Top Page
iFabric
(TSX:IFA)
iFabric (IFA) vs. iShares MSCI Canada ETF (EWC)
iFabric Business Overview & Revenue Model
iFabric Earnings Call Summary
iFabric Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 27.33M | 22.72M | 19.74M | 19.76M | 11.52M |
| Gross Profit | 11.27M | 8.84M | 7.03M | 7.76M | 4.30M |
| EBITDA | 2.11M | -2.21M | -27.09K | 3.21M | -551.96K |
| Net Income | 1.63M | -1.69M | -452.46K | 2.37M | -624.71K |
Balance Sheet | |||||
| Total Assets | 29.49M | 25.91M | 27.37M | 27.63M | 17.51M |
| Cash, Cash Equivalents and Short-Term Investments | 2.06M | 1.57M | 944.73K | 8.90M | 1.16M |
| Total Debt | 1.88M | 2.03M | 1.24M | 1.27M | 1.32M |
| Total Liabilities | 6.35M | 5.21M | 4.60M | 5.35M | 8.17M |
| Stockholders Equity | 23.13M | 20.69M | 22.75M | 22.27M | 9.34M |
Cash Flow | |||||
| Free Cash Flow | 208.92K | 644.99K | -8.45M | -2.48M | -1.24M |
| Operating Cash Flow | 301.78K | 833.77K | -8.21M | -2.22M | -1.06M |
| Investing Cash Flow | -52.86K | -138.38K | -242.76K | -253.40K | -178.02K |
| Financing Cash Flow | -214.74K | -14.42K | 41.93K | 10.46M | 205.15K |
iFabric Technical Analysis
iFabric Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $11.93B | 18.28 | 31.12% | 1.51% | 6.64% | 27.37% | |
70 Outperform | $1.88B | 41.01 | 11.35% | ― | 2.45% | -17.73% | |
66 Neutral | C$35.15M | 38.03 | 4.36% | ― | 18.44% | ― | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
52 Neutral | C$54.56M | ― | -1.67% | ― | 22.39% | 90.55% | |
46 Neutral | C$23.77M | -8.92 | -16.28% | ― | -3.10% | 67.01% |
iFabric Corporate Events
iFabric Corp has secured a $2.5 million unsecured trade finance facility with Ebury Partners Canada Ltd. to enhance financial flexibility for growth and expansion. This facility, alongside an existing $12 million secured credit facility, is expected to support iFabric’s sales growth objectives and help manage foreign currency risks, reflecting a strategic move to strengthen its market position.
The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.
iFabric Corp’s subsidiary, IFTNA, has entered a licensing agreement with Mercury Athletics LLC to design, manufacture, and market scrubs and medical apparel under the Doctor’s Choice brand. This collaboration aims to integrate IFTNA’s textile technologies, including PROTX2®, to enhance infection-prevention and comfort in healthcare apparel, potentially strengthening iFabric’s position in the healthcare sector.
The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.
iFabric Corp. has announced the renewal of its license agreement with TUMI, Inc., allowing the continued integration of its PROTX2® antimicrobial solutions in select TUMI products for another five years. This partnership highlights the commitment of both companies to deliver performance, durability, and protection in travel essentials, with PROTX2 being featured in various TUMI collections, enhancing their product offerings with eco-friendly antimicrobial solutions.
The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.
iFabric Corp. has announced the expansion of its PROTX2 technology into the UK and EU markets, with Marks & Spencer adopting this technology for its Autograph collections. This strategic move marks iFabric’s shift beyond its North American focus, highlighting growing global demand for performance-enhanced fabrics and reinforcing its presence in new regional markets.
The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.
iFabric Corp. has announced the publication of a clinical trial demonstrating the effectiveness of their PROTX2® and ecoPEL™ treated scrubs in reducing bacterial contamination in healthcare environments. The study, published in the Journal of Hospital Infection, highlights significant reductions in bacterial loads on scrubs, positioning iFabric’s technologies as a leading solution in infection prevention. This breakthrough offers substantial market opportunities for iFabric, as it addresses a critical need in healthcare-associated infection control, potentially reducing infection rates, readmissions, and hospital costs while extending protection beyond hospital settings.
The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.
iFabric Corp reported its financial results for Q2 and H1 2025, showing stable revenues despite challenges such as U.S. tariffs and exchange losses. The company experienced a slight decrease in overall revenues due to brand advertising contributions and a weakening U.S. dollar, but it remains optimistic about future growth, with record-level deposits for future deliveries. The Intimate Apparel Division saw a 10% revenue increase, while the Intelligent Fabrics Division faced a 7% decline. iFabric is poised for expansion in the U.S. market, supported by strategic supplier and customer negotiations.